Condition: Colorectal Cancer · Pancreatic Cancer · Gastric Cancers · Sponsor: Bold Therapeutics, Inc.
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.
This description comes directly from the study's public registry record.
Michelle Jones · 604-262-9899 · clinical@bold-therapeutics.com
Jim Pankovich · 604-262-9934 · jp@bold-therapeutics.com
Always discuss trial participation with your own doctor first.
| University of California, Los Angeles | Santa Monica, California, United States | Completed |
| Moffitt Cancer Center | Tampa, Florida, United States | Completed |
| Cross Cancer Institue | Edmonton, Alberta, Canada | Recruiting |
| Juravinski Cancer Centre | Hamilton, Ontario, Canada | Recruiting |
| The Ottawa Hospital Cancer Centre | Ottawa, Ontario, Canada | Recruiting |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
| Jewish General Hospital | Montreal, Quebec, Canada | Recruiting |
| McGill University Health Centre Glen Site | Montreal, Quebec, Canada | Recruiting |
| Universitatsklinikum Bonn | Bonn, Germany | Recruiting |
| University Hospital of Ulm | Ulm, Germany | Recruiting |
| Mater Miserecordiae University Hospital | Dublin, Ireland | Recruiting |
| St. James Hospital | Dublin, Ireland | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04421820